Recombinant Protein Production: Advancements And Applications
Main Article Content
Abstract
Recombinant gene production has become a cornerstone of modern biotechnology, offering revolutionary solutions in various fields. This abstract explores the diverse applications of recombinant gene technology, highlighting its pivotal role in medicine, agriculture and industry, while also discussing the latest advancements and challenge. Recombinant gene production involves the deliberate manipulation of genetic material to create hybrid DNA sequences with desired traits. This technology has enabled the synthesis of therapeutic proteins, vaccines and enzymes that were once scarce or inaccessible. In medicine recombinant gene expression systems have revolutionized the treatment of various diseases, ranging from insulin production for diabetesb management to monoclonal antibody therapies for cancer treatment. In agriculture, recombinant gene technology has been harnessed to develop genetically modified crops with enhanced nutritional content, resistance to pests and diseases and improve yield. These advancements hold promise for addressing global food security challenges, although they also raise concerns about ecological impact and consumer
acceptance. Industrial applications of recombinant gene production encompass the production of biofuels, bioplastics and wide array of biobased chemicals. This technology enables the cost effective production of valuable compounds through microbial fermentation or other bioprocesses, contributing to sustainable manufacturing practices. Recent advancements in recombinant gene production include the development of novel expression systems such as synthetic biology tools that enable precise control over gene expression and metabolic pathways. Additionally, innovations like CRISPR based genome editing have accelerated the modification of host organisms for improved recombinant protein yields and functionalities. Despite its transformative potential, recombinant gene production faces challenges. Ensuring the safety and regulatory compliance of genetically modified products remain a priority. Furthermore, optimising expression systems to maximize yields, scalability, and post translational modifications is ongoing endeavour
Downloads
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
. Adrio, J. L., & Demain, A. L. (2010). Recombinant organisms for production of industrial
products. Bioengineered bugs, 1(2), 116–131. https://doi.org/10.4161/bbug.1.2.10484
Davami, F., Barkhordari, F., Alebouyeh, M., Adeli, A., & Mahboudi, F. (2011). Combined TGE-SGE
expression of novel PAI-1-resistant t-PA in CHO DG44 cells using orbitally shaking disposable
bioreactors. Journal of microbiology and biotechnology, 21(12), 1299–1305.
https://doi.org/10.4014/jmb.1106.05060
Gifre, L., Arís, A., Bach, À., & Garcia-Fruitós, E. (2017). Trends in recombinant protein use in animal
production. Microbial cell factories, 16(1), 40. https://doi.org/10.1186/s12934-017-0654-4
Gupta, V., Sengupta, M., Prakash, J., & Tripathy, B. C. (2016). Production of Recombinant Pharmaceutical
Proteins. Basic and Applied Aspects of Biotechnology, 77–101. https://doi.org/10.1007/978-981-10-0875-
_4
Kamionka M. (2011). Engineering of therapeutic proteins production in Escherichia coli. Current
pharmaceutical biotechnology, 12(2), 268–274. https://doi.org/10.2174/138920111794295693
Kim, K. H., Jia, X., Jia, B., & Jeon, C. O. (2018). Identification and Characterization of l-Malate
Dehydrogenases and the l-Lactate-Biosynthetic Pathway in Leuconostoc mesenteroides ATCC
Journal of agricultural and food chemistry, 66(30), 8086–8093.
https://doi.org/10.1021/acs.jafc.8b02649
Mital, S., Christie, G., & Dikicioglu, D. (2021). Recombinant expression of insoluble enzymes in
Escherichia coli: a systematic review of experimental design and its manufacturing implications. Microbial
cell factories, 20(1), 208. https://doi.org/10.1186/s12934-021-01698-w
Swiech, K., Kamen, A., Ansorge, S., Durocher, Y., Picanço-Castro, V., Russo-Carbolante, E. M., Neto, M.
S., & Covas, D. T. (2011). Transient transfection of serum-free suspension HEK 293 cell culture for efficient
production of human rFVIII. BMC biotechnology, 11, 114. https://doi.org/10.1186/1472-6750-11-114
Kesik-Brodacka M. (2018). Progress in biopharmaceutical development. Biotechnology and applied
biochemistry, 65(3), 306–322. https://doi.org/10.1002/bab.1617
Dhillon S. (2012). Octocog alfa, antihaemophilic factor (recombinant), plasma/albumin free method
(Advate®): a review of its use in the management of patients with haemophilia A. Drugs, 72(7), 987–1007.